Format

Send to

Choose Destination
Clin Pharmacol Ther. 2013 Jul;94(1):23-6. doi: 10.1038/clpt.2013.12.

International Transporter Consortium commentary on clinically important transporter polymorphisms.

Author information

1
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA. kathy.giacomini@ucsf.edu

Abstract

This Commentary focuses on genetic polymorphisms in membrane transporters. We present two polymorphisms for which there is a compelling body of literature supporting their clinical relevance: OATP1B1 (c.521T>C, p.V174A, rs4149056) and BCRP (c.421C>A, p.Q141K, rs2231142). The clinical evidence demonstrating their role in variation in pharmacokinetics and pharmacodynamics is described along with their allele frequencies in ethnic populations. Recommendations for incorporating studies of transporter polymorphisms in drug development are provided, along with the regulatory implications.

PMID:
23778707
DOI:
10.1038/clpt.2013.12
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center